Press Releases
Press Releases
Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor
ELC GROUP, one of the fastest-growing providers of regulatory affairs consulting services, today announced that John Warren, a former Expert Medical Assessor for the UK Medicines Healthcare products Regulatory Agency (MHRA) has joined the ELC GROUP Advisory Board. ...
Press Releases
First Country in Europe launches LATUDA® – a New Atypical Antipsychotic for Adults with Schizophrenia
LATUDA® (lurasidone), a new once-daily treatment for schizophrenia, is now available in Switzerland for the treatment of schizophrenia.Research has shown that the atypical antipsychotic, lurasidone, has a specific receptor binding profile. Symptom control and reducing...
Press Releases
Veristat to Assist on Adaptive Enrichment Trial for Verastem’s Defactinib in Mesothelioma
Veristat LLC. a leading Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem Inc. . The enhanced design aims to optimize the current trial of defactinib a novel...
Press Releases
Oncodesign and Banook Central Imaging sign a collaboration agreement to develop biomarkers in clinical imaging
Oncodesign, a contract research laboratory dedicated to the discovery of new anticancer therapies, and Banook Central Imaging, a company specializing in the centralized reading of medical images, today announce the start of a partnership to expand the use of...
Press Releases
Almac and Queen’s University, Belfast announce £13 million investment in Cancer Research
Almac Discovery has announced a £13million partnership with the Centre for Cancer Research and Cell Biology (CCRCB) at Queen’s University Belfast (QUB) to accelerate cancer-focused drug discovery in Northern Ireland. As part of the partnership,...
Press Releases
PharmaEngine Announces Achieving Patient Enrollment Goal in the Phase III Metastatic Pancreatic Cancer Study of PEP02
PharmaEngine Inc. announced today that together with PharmaEngine’s partner Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) we reach the goal of patient enrollment in the global phase 3 metastatic pancreatic cancer study of PEP02 (MM-398). The total target number of patient...
Press Releases
Infraredx Receives $25 Million Investment from Nipro Corporation
Infraredx Inc. a medical device company committed to advancing the diagnosis and management of coronary artery disease today announced that it has received a $25 million equity investment from Nipro Corporation. This investment builds on...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read